Floatz logo

ss1 pe38

Malignant Mesothelioma

National Cancer Institute (NCI)Phase 1Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

29 Active assets in the Malignant Mesothelioma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Dr Jean Yannis PERENTES
Phase 2BB
Inno-206
Mayo Clinic
Phase 2BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 2BB
Sargramostim
Memorial Sloan Kettering Cancer Center
Phase 2BB
Alpha-Interferon
St. Vincent Medical Center - Los Angeles
Phase 2B

View all 50 →

Same molecule, other indications

ss1 pe38 is also rated in:

pancreatic neoplasmDormant
CCC
Indicative ·
55 / 100
View asset →
lung adenocarcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →